본문 바로가기
  • Home

Treatment of two cases of chronic kidney disease with dietotherapy (ilaj-bil-ghiza), regimenal therapy (bukhoor aam) and Unani drugs without dialysis

  • CELLMED
  • Abbr : CellMed
  • 2020, 10(2), pp.17-17
  • DOI : 10.5667/CellMed.2020.0017
  • Publisher : Cellmed Orthocellular Medicine and Pharmaceutical Association
  • Research Area : Medicine and Pharmacy > General Medicine
  • Received : November 1, 2019
  • Accepted : February 17, 2020
  • Published : May 29, 2020

Shabnam Ansari 1 Mohammad Maaz 2 Shah Alam 3 Sazid Alam 4 Ijhar Ahmad 5

1Department of Biotechnology, Faculty of Natural Sciences, Jamia Millia Islamia
2Department of Moalajat, School of Unani medical education and research, Jamia Hamdard
3Central council for research in Unani medicine
4Department of Moalajat (Medicine), Sufia Unani medical college hospital and research center
5Jamia Hamdard

Candidate

ABSTRACT

Background: Chronic kidney disease (CKD) is affective a large portion of the world population prompting the need for extensive healthcare resources such as lifelong dialysis or kidney transplantation. The beneficial effect of conventional therapy in controlling the CKD progression remains a challenge due to their relative efficacy, safety, and accessibility. On the other hand, Unani medicine provides a therapeutic regimen that consists of a combination of treatment from rehabilitation to herbal pharmacotherapy. Methods: Two cases of chronic kidney disease were treated with dietotherapy, regimenal therapy (‘bukhoor aam’) and oral herbal drugs for 2-3 weeks. Endpoints of evaluation were symptoms and signs of the CKD, kidney function test, urine albumin, urine RBC, hemoglobin and liver function test. Result: Notable improvement was observed in the endpoints. Conclusion: Unani treatment was observed preliminarily beneficial in the treatment of chronic kidney disease. Rigorous pharmacological and clinical studies should be performed to warrant their efficacy and safety in CKD individuals.

Citation status

* References for papers published after 2022 are currently being built.